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Cryptococcosis, caused by the basidiomycetous fungus Cryptococcus neoformans, is responsible for more than 600,000 deaths
annually in AIDS patients. Flucytosine is one of the most commonly used antifungal drugs for its treatment, but its resistance
and regulatory mechanisms have never been investigated at the genome scale in C. neoformans. In the present study, we per-
formed comparative transcriptome analysis by employing two-component system mutants (tco1 and tco2) exhibiting oppos-
ing flucytosine susceptibility. As a result, a total of 177 flucytosine-responsive genes were identified, and many of them were
found to be regulated by Tco1 or Tco2. Among these, we discovered an APSES-like transcription factor, Mbs1 (Mbp1- and Swi4-
like protein 1). Expression analysis revealed that MBS1 was regulated in response to flucytosine in a Tco2/Hog1-dependent man-
ner. Supporting this, C. neoformans with the deletion of MBS1 exhibited increased susceptibility to flucytosine. Intriguingly,
Mbs1 played pleiotropic roles in diverse cellular processes of C. neoformans. Mbs1 positively regulated ergosterol biosynthesis
and thereby affected polyene and azole drug susceptibility. Mbs1 was also involved in genotoxic and oxidative stress responses.
Furthermore, Mbs1 promoted production of melanin and capsule and thereby was required for full virulence of C. neoformans.
In conclusion, Mbs1 is considered to be a novel antifungal therapeutic target for treatment of cryptococcosis.
Cryptococcus neoformans is a basidiomycetous fungus that hasboth saprobic and parasitic life cycles. In the natural environ-
ment, including soil, trees, and pigeon guano, C. neoformans exists
as both yeast and filamentous forms and undergoes sexual differ-
entiation with cells of the opposite mating type (MAT and MATa
cells) and monokaryotic fruiting with the same mating type. Upon
inhalation of its dried yeast form or basidiospores through the
respiratory tract, a susceptible host may develop fungal pneumo-
nia and fatal meningoencephalitis by subsequent dissemination of
the pathogen, particularly to the central nervous system (CNS)
(24, 34). A recent retrospective epidemiological study shows that
approximately 957,000 cases of HIV/AIDS-related cryptococcal
meningitis, which result in more than 600,000 deaths within 3
months after infection, occur annually worldwide (46). However,
cryptococcal meningitis is not limited to just the immunocom-
promised populations, as witnessed by the emergence of Crypto-
coccus gattii in the Pacific Northwest region of Canada and the
United States since 1999 (16), which has caused fatal diseases in
immunocompetent individuals.
Despite global concerns, only a limited number of antifungal
agents, such as amphotericin B (AMB), flucytosine, and azole drugs,
are clinically available for treatment of cryptococcosis. Unfortu-
nately, these antifungal drugs have inherent problems, such as toxic-
ity to multiple organs, including liver and kidney, and the emergence
of resistant strains (3, 4, 9, 52). The narrow option of available anti-
fungal drugs led researchers not only to aim to develop novel antifun-
gal targets but also to attempt various combination therapies to yield
synergistic antifungal effects. The major advantages of combination
antifungal therapy include reduction of the dose and toxicity inherent
to each drug, potential decrease in the number of drug-resistant
strains, and broadening of the antifungal spectrum (3, 39, 49). Several
fungal signaling pathways have been recognized to be potentially
good targets for development of combination therapy with azole or
polyene drugs with synergistic anticryptococcal effects (14, 18, 27, 29,
32, 40). In contrast, targets for combination therapy with flucytosine
are relatively poorly known. Flucytosine, a fluorinated analogue of
cytosine, is known to be effective in treatment of candidiasis and
cryptococcosis (52) and is highly recommended in combination with
AMB for initial treatment of acute fungal meningitis and cryptococ-
cosis (9, 50). Despite this clinical importance, the regulatory and re-
sistance mechanisms for flucytosine in C. neoformans are poorly un-
derstood and have generally been assumed to be similar to those of
Saccharomyces cerevisiae and Candida albicans (55). Flucytosine is
transported into the cell by membrane-bound cytosine permease and
converted to 5-fluorouracil by cytosine deaminase. Subsequently,
5-fluorouracil is converted to 5-fluoro-UMP by uracil phosphoribo-
syltransferase (UPRT), which is further metabolized to either
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5-fluoro-UTP or 5-fluoro-2=-deoxyuridylate, the last two of which
inhibit RNA and DNA synthesis, respectively (52).
Here we found that a C. neoformans strain lacking the hybrid
sensor kinase Tco1 or Tco2 exhibited differential susceptibility to
flucytosine, suggesting that the two-component system may be
involved in a flucytosine resistance mechanism. The cryptococcal
two-component system, composed of hybrid sensor kinases
(Tco1/2), phosphotransfer protein (Ypd1), and response regula-
tors (Ssk1 and Skn7), activates the Ssk2-Pbs2-Hog1 mitogen-
activated protein kinase (MAPK) module (6, 7, 33). Hog1 subse-
quently activates a plethora of downstream target genes which
control a variety of cellular functions in C. neoformans, including
stress response, sexual differentiation, ergosterol biosynthesis,
and production of two major virulence factors, capsule and mel-
anin (6, 29). Notably, perturbation of the two-component system
and HOG pathway dramatically increases susceptibility to poly-
ene drugs, such as AMB, mainly due to increased cellular ergos-
terol content (29). To identify and characterize the flucytosine-
responsive genes in C. neoformans at the genome level, we
performed a comparative transcriptome analysis of the wild-type
(WT) strain and tco1, tco2, and hog1 mutants grown with or
without flucytosine. Among 194 genes identified, we discovered a
gene (CNAG_07464.2) that is predicted to encode a protein ho-
mologous to the yeast Mbp1 and Swi4 and therefore named it
MBS1 (Mbp1- and Swi4-like protein 1). In S. cerevisiae, Mbp1 is a
DNA-binding protein that forms the MBF (MCB binding factor)
complex with Swi6. During the cell cycle, MBF is involved in the
G1/S transition along with the SBF (Swi4/6 cell cycle box [SCB]
binding factor) complex, which consists of Swi4 and Swi6. Mbp1
is homologous to Swi4, and double mutation of MBP1 and SWI4
causes lethality, indicating that Mbp1 and Swi4 play overlapping
roles for the G1/S transition in cell cycle progression (31). Mbp1
and Swi4 show limited but significant homology to fungal APSES
proteins (19, 31, 48). The APSES transcription factors belong to
the basic helix-loop-helix (bHLH) class of transcription factors,
which is widely conserved in eukaryotic organisms, although the
APSES domain itself is exclusively found in the fungal kingdom
(19, 48). The APSES family of transcriptional regulatory proteins
plays crucial roles in controlling morphological differentiation
and virulence attributes in diverse fungal species (2, 20, 21, 36, 42,
43, 51, 54).
In this study, a variety of molecular and genetic analyses re-
vealed that Mbs1 is indeed a flucytosine-responsive Mbp1/Swi4-
like protein in the Tco2- and Hog1-related signaling pathways and
plays pleiotropic roles in antifungal drug resistance by controlling
ergosterol biosynthesis, oxidative and genotoxic stress response,
and virulence of C. neoformans. Therefore, this study not only
reports the first cryptococcal APSES-like protein but also may
have identified a novel antifungal therapeutic method for treat-
ment of cryptococcosis.
MATERIALS AND METHODS
Strains and growth media. The strains and primers used in this study are
listed in Tables S1 and S2 in the supplemental material. C. neoformans
strains were cultured in yeast extract-peptone-dextrose (YPD) medium
unless indicated otherwise. Agar-based Dulbecco modified Eagle (DME)
medium for capsule production and L-3,4-dihydroxyphenylalanine (L-
DOPA) medium or Niger seed medium for melanin production were
prepared as described previously (1, 5, 22, 26).
Antifungal drug and stress susceptibility tests. To assess stress re-
sponse and antifungal drug susceptibility, cells grown overnight at 30°C in
YPD medium were serially diluted (1 to 104 dilutions) with sterile H2O.
Then 3 to 4 l of cell suspension of each strain was spotted onto solid YPD
or yeast extract-peptone (YP) agar medium containing the indicated con-
centrations of flucytosine, amphotericin B, fluconazole, ketoconazole,
itraconazole, or fludioxonil for antifungal drug susceptibility testing;
NaCl or KCl for osmosensitivity test; hydrogen peroxide, diamide, or
tert-butyl hydroperoxide for oxidative stress susceptibility test; hy-
droxyurea or methyl methanesulfonate for genotoxic stress susceptibility
test; and cadmium sulfate for heavy metal stress test. Plates were observed
after 2 to 4 days of incubation at 30°C and photographed.
Total RNA isolation and DNA microarray analysis. Total RNA for
DNA was obtained by growing the WT H99 strain and tco1 (YSB355),
tco2 (YSB281), and hog1 (YSB64) mutant strains in 50 ml YPD me-
dium at 30°C for 16 h. Then 5 ml of the overnight culture was inoculated
into 100 ml of fresh YPD medium and further incubated for 4 h at 30°C to
an optical density at 600 nm (OD600) of 1.0. The inoculated 100 ml YPD
medium was divided into two 50-ml flasks, one with and one without 25
g/ml flucytosine treatment, and both flasks were incubated for 90 min at
30°C. Then the culture was frozen in liquid nitrogen and lyophilized over-
night. Three independent cultures for each strain were prepared for total
RNA isolation as biological replicates. Total RNAs were isolated by the
TRIzol reagent (Molecular Research Center) as described before (29). The
concentration and purity of total RNA samples were measured by deter-
mination of the OD260 and gel electrophoresis. As control total RNAs for
identifying flucytosine-responsive genes, all total RNAs prepared from
WT and tco1, tco2, and hog1 mutant cells grown under the conditions
described above were pooled as reference RNAs.
For DNA microarray analysis, we used a C. neoformans serotype D
70-mer microarray slide containing 7,936 probes (Duke University). The
cDNA was synthesized by using AffinityScript reverse transcriptase (Strat-
agene), labeled by Cy5/Cy3 labeling agents (Amersham), hybridized to
microarray slides, and then washed as described previously (29). Three
independent DNA microarray analyses with three independent biological
replicates were performed. Subsequently, hybridized chips were scanned
with a GenePix 4000B scanner (Axon Instrument) and the signals were
processed with the program GenePix Pro (version 4.0) and the GenePix
array list (GAL) file (http://genome.wustl.edu/activity/ma/cneoformans).
Microarray data analysis was performed as described previously (40). For
hierarchical and statistical analysis, data transported from GenePix soft-
ware were analyzed with Accuity software by employing Lowess normal-
ization, reliable gene filtering (95% filtering), hierarchical clustering,
zero transformation, analysis of variance (ANOVA) (P  0.05), and Mi-
crosoft Excel software (Microsoft).
Northern blot analysis and quantitative real-time reverse
transcription-PCR. Quantitative real-time reverse transcription-PCR
(qRT-PCR) for quantitatively measuring relative expression levels of
MBS1 and ERG11 was performed with primers listed in Table S2 in the
supplemental material and with cDNAs that were generated using the
SuperScript II reverse transcriptase system with total RNAs used in DNA
microarray analysis. Relative gene expression was calculated by the
2CT (where CT is cycle threshold) method (35). ACT1 was used for
normalization of gene expression. Northern blot analysis for monitoring
expression levels of FCY1, FCY2, FCY4, FUR1, and MBS1 was performed
as described previously (26).
Mutant and complemented strain construction. The mbs1 mutants
were generated in the congenic C. neoformans serotype A MAT (H99)
and MATa (KN99a) strain background by overlap PCR by using H99 or
KN99a genomic DNA and primers listed in Table S2 in the supplemental
material as described previously (6, 17). Positive mutant strains were
screened by using diagnostic PCR screening primers and further con-
firmed by Southern blot analysis with a genomic DNA digested with ap-
propriate restriction enzymes, and each gene-specific probe was amplified
by PCR with primers listed in Table S2 in the supplemental material (see
also Fig. S2B in the supplemental material).
To verify mutant phenotypes, the mbs1/MBS1 complemented
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strains were constructed by reintegrating the WT MBS1 gene into the
native MBS1 locus as follows. First, the full-length MBS1 gene, which
contains 1,077 bp of the 5= untranslated region (UTR), 2,301 bp of the
MBS1 open reading frame (ORF), and 400 bp of the 3= UTR, was ampli-
fied by PCR with H99 genomic DNA as a template and primers B1958 and
B1959 containing a NotI recognition site and directly cloned into the TOP
vector (Enzynomics) to generate plasmid pCR-MBS1. After confirming
the DNA sequence, the MBS1 insert was subcloned into plasmid pJAF12
(NEOr) to produce plasmid pNEOMBS1. For the targeted reintegration of
the WT MBS1 allele into its native locus, pNEOMBS1 was linearized by
digestion with MfeI, of which the restriction site is uniquely present in the
MBS1 promoter region of the plasmid, and biolistically transformed into
the mbs1 mutant (YSB488). Targeted reintegration of the MBS1 gene
into its native locus (YSB1195) was confirmed by diagnostic PCR with the
primer pair of B1216, which binds upstream of the MBS1 promoter region
of pNEOMBS1, and B2303, which binds to the 4th exon of the MBS1
coding sequence (see Fig. S2A and C in the supplemental material).
Cytosine uptake by fungal cells. Cytosine uptake in the WT H99
strain, along with the tco1 and tco2 mutants, was determined using
[3H]cytosine (specific activity, 20 Ci/mmol; Moravek Biochemicals).
Cells were grown overnight in YPD medium at 30°C for 48 h to an OD600
of typically between 2.0 and 4.0. Cells were subsequently harvested by
centrifugation (3,000  g, 5 min) and washed twice with YNB complete
medium (1.7 g yeast nitrogen base without amino acids or ammonium
sulfate, 5 g ammonium sulfate per liter, pH 5.0) with or without glucose
(for starvation) and without supplementation. Cells were resuspended at
a cell density corresponding to an absorbance at 600 nm of 30 in YNB
medium for 3 h for glucose starvation and then incubated in the presence
of 50 nM [3H]cytosine. Samples (100 l) were removed at 1 h, 3 h, and 24
h and placed into stop solution (YNB medium plus 20 M [3 mg/ml]
fluconazole), filtered on glass fiber filters (pore size, 24 mm; GF/C; What-
man, Kent, United Kingdom) made wet beforehand with stop solution,
and washed once with 5 ml of stop solution. Filters were transferred to
20-ml scintillation vials. Scintillation cocktail (Ecoscint XR; National
Diagnostics, Atlanta, GA) was added (15 ml), and the vials were left at
room temperature overnight before they were read. The radioactivity as-
sociated with the filter was measured with a liquid scintillation analyzer
(Tri-Carb 2800 TR; Perkin Elmer, Waltham, MA) and normalized to
cpm/1  108 cells. Samples were analyzed for [3H]cytosine accumulation
at designated time points.
Assays for melanin, capsule, and ergosterol production. Qualitative
visualization and quantitative measurement of capsule and melanin pro-
duction were performed as described previously (26, 28). Ergosterol ex-
traction and calculation of ergosterol content were done following the
method outlined by Ko et al. (29).
Virulence assay. All animal experiments were done at the University
of Minnesota in strict accordance with good animal practice as defined by
the National Institutes of Health Office of Laboratory Animal Welfare
(OLAW) and the Association for the Assessment and Accreditation of
Laboratory Animal Care (AAALAC). All experiments were reviewed and
approved by the University of Minnesota Institutional Animal Care and
Use Committee (IACUC) under protocol number 1010A91133. Over-
night cultures of C. neoformans strain H99 and the mbs1 (YSB488) and
mbs1/MBS1 (YSB1195) mutants were grown in YPD broth at 30°C. The
resulting cultured yeast cells were pelleted and washed three times in
sterile phosphate-buffered saline (PBS). For each strain, hemocytometer
counts were utilized to adjust cell concentrations to 1  106 cells/ml.
Groups of 10 6- to 8-week-old female A/J mice (Jackson Laboratory, Bar
Harbor, ME) were anesthetized by intraperitoneal pentobarbital injec-
tion. Using a murine inhalation model, 5  104 cells in 0.05 ml PBS were
instilled into the nares of anesthetized mice. The concentration of the
initial inoculum was confirmed by plating serial dilutions on YPD agar
and enumerating the CFU. Mice were monitored daily for signs of severe
morbidity (weight loss, abnormal gait, extension of the cerebral portion of
the cranium). Animals exhibiting these signs were sacrificed by CO2 in-
halation. Homogenized lung, spleen, and brain tissues from representa-
tive animals from each infection were plated onto YPD agar containing
chloramphenicol (100 mg/ml) to determine the numbers of CFU and the
extent of dissemination. Survival data were analyzed by the Analyze-It for
Excel program. The Mann-Whitney U test was performed to analyze dif-
ferences between survival curves, and P values of 0.05 were considered
significant.
Tissue analysis. Groups of 3 mice were infected with 5  104 cells of
the H99, mbs1, or mbs1/MBS1 strain as described above. Infected mice
were sacrificed at 21 days postinfection by CO2 inhalation. The lungs and
brain were harvested, fixed in 10% buffered formalin, paraffin embedded,
sectioned, and stained with hematoxylin and eosin (H&E). Tissue sections
were examined for cell size and morphology, as well as signs of host im-
mune response, by microscopy.
Titan cell formation. Three mice per treatment were infected with 5 
106 cells of the H99, mbs1, or mbs1/MBS1 strain as described above. At
3 days postinfection, animals were sacrificed by CO2 inhalation. Lungs
were lavaged with 1.5 ml sterile PBS three times using a 20-gauge needle
placed in the trachea. Cells in the lavage fluid were pelleted at 16,000  g
and subjected to a 30-min room temperature fixation in a 3.7% formal-
dehyde solution. Cells were subsequently washed once with PBS, resus-
pended in PBS, and analyzed for size and morphology by microscopy. A
minimum of 300 cells per animal were analyzed to determine the extent of
titan cell formation. One-way ANOVA was used to analyze differences in
titan cell production. P values of less than 0.05 were considered signifi-
cant.
Microarray data accession number. The whole microarray data gen-
erated by this study have been submitted to the Gene Expression Omnibus
(GEO; http://www.ncbi.nlm.nih.gov/geo/) under accession no.
GSE30154.
RESULTS
Role of hybrid sensor kinases Tco1 and Tco2 in flucytosine re-
sistance of C. neoformans. To find synergistic cellular targets for
combination therapy with flucytosine, we tested the flucytosine
susceptibility of different two-component system and HOG sig-
naling mutants in C. neoformans. Cells with Hog1 MAPK (hog1),
Pbs2 MAPKK (pbs2), and Ssk2 MAPKKK (ssk2) deletions were
slightly more susceptible to flucytosine than the WT strain (Fig.
1A). Intriguingly, two major hybrid sensor kinases, Tco1 and
Tco2, appeared to control flucytosine resistance in C. neoformans
in opposing manners (Fig. 1A). Mutation of TCO1, which en-
codes a HAMP repeat-containing hybrid sensor kinase, enhanced
flucytosine susceptibility, whereas mutation of TCO2, which en-
codes a double-hybrid sensor kinase, conferred flucytosine resis-
tance (Fig. 1A). In contrast, other hybrid sensor kinase mutants,
including tco3, tco4, tco5, and tco7 mutants, showed WT
levels of susceptibility to flucytosine (Fig. 1A). These results indi-
cate that the two-component phosphorelay system may be in-
volved in flucytosine resistance in C. neoformans.
Involvement of the two-component phosphorelay system in
flucytosine resistance has not been reported in other fungi. There-
fore, we investigated how the phosphorelay system and hybrid
sensor kinase mutants show differential susceptibility against flu-
cytosine in C. neoformans. The general mode of action for devel-
oping flucytosine resistance has been well characterized in
other fungi (52) (see Fig. S1 in the supplemental material). C.
neoformans contains homologs of cytosine permease genes
(CNAG_01681.2, CNAG_04982.2, and CNAG_04276.2; we
named them FCY2, FCY3, and FCY4, respectively) and cytosine
deaminase genes (CNAG_00613.2, which we named FCY1), and
the UPRT gene (CNAG_02337.2, which we named FUR1) (see
Fig. S1 in the supplemental material). Therefore, the flucytosine
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resistance observed in the two-component system mutants could
be the result of altered expression of genes encoding cytosine per-
mease, cytosine deaminase, or UPRT (11, 52).
To compare flucytosine uptake levels between the WT strain
and tco1 and tco2 mutants, we measured intracellular accumu-
lation of radiolabeled cytosine in the WT strain and tco1 and
tco2 mutants based on the fact that flucytosine is transferred into
the cell and metabolized similarly to exogenously added cytosine.
Lack of Tco1 and Tco2 did not affect cellular uptake of cytosine
under either glucose-rich or glucose-starved conditions (Fig. 1B).
Supporting this finding, expression levels of the cytosine permease
genes FCY2 and FCY4 in the tco1 or tco2 mutant were found to
be similar to those in the WT strain before and after flucytosine
treatment (Fig. 1C). Transcript abundance of FCY3 was too low to
be detected in the WT strain and tco1 and tco2 mutants (data
not shown). Expression levels of FCY1 were also not altered in the
WT strains and tco1 mutant in response to flucytosine. However,
FCY1 expression was induced in the tco2 mutant upon flucyto-
sine treatment (Fig. 1D). FUR1 expression was not significantly
altered in the WT strain and tco1 and tco2 mutants upon flu-
cytosine treatment (Fig. 1D). Interestingly, basal expression levels
of FUR1 and FCY1 appeared to be higher in the hog1 mutant
than WT (Fig. 1D). Nevertheless, these expression patterns of
genes involved in the salvage pathway of cytosine metabolism did
not appear to be correlated with the differential flucytosine sus-
ceptibility patterns observed in the tco1 and tco2 mutants.
Hence, we concluded that the differential flucytosine resistance
observed in tco1 and tco2 mutants may result from aberrant
regulation of a signaling or metabolic pathway(s) other than the
salvage pathway of cytosine metabolism.
Comparative transcriptome analysis of the tco1, tco2, and
hog1 mutants in response to flucytosine treatment. To address
how Tco1, Tco2, and Hog1 differentially regulate flucytosine re-
sistance and to discover genes that are regulated by flucytosine in
C. neoformans, we performed comparative transcriptome analysis
of the WT strain and tco1, tco2, and hog1 mutants with or
without flucytosine treatment. Previously, Zhang and coworkers
performed a similar transcriptome analysis to find flucytosine-
responsive genes by using DNA microarray analysis with total
RNA isolated from Saccharomyces cerevisiae grown in YPD me-
dium containing 25 g/ml flucytosine for 90 min (57). We found
that the concentration of 25 g/ml was also close to a sublethal
concentration of flucytosine without affecting cell viability of C.
neoformans at a 90-min incubation time (data not shown). There-
fore, we decided to use the same concentration and incubation
time for flucytosine treatment for total RNA isolation from C.
neoformans strains, which allowed us to compare transcriptome
profiles for flucytosine-responsive genes between C. neoformans
and S. cerevisiae. The whole microarray data set is presented in
Table S3 in the supplemental material.
Based on our transcriptome analysis, a total of 177 C. neofor-
mans genes were up- or downregulated more than 2-fold in re-
sponse to flucytosine (Fig. 2A to C; see Table S4 in the supplemen-
tal material). Among these, 118 genes encode proteins that do not
FIG 1 Role of the two-component system and the HOG pathway in flucytosine susceptibility of C. neoformans. (A) Each C. neoformans strain (WT [H99], hog1
[YSB64], pbs2 [YSB123], ssk2 [YSB264], ssk1 [YSB261], skn7 [YSB349], tco1 [YSB278], tco2 [YSB281], tco3 [YSB284], tco4 [YSB417], tco5
[YSB286], and tco7 [YSB348]) was grown overnight at 30°C in liquid YPD medium, 10-fold serially diluted (1 to 104 dilutions), and spotted (3 l of dilution)
on YPD agar containing the indicated concentrations of flucytosine. Cells were incubated at 30°C for 72 h and photographed. (B) Cytosine uptake test. Uptake
of radiolabeled cytosine ([3H]cytosine) into the WT strain and tco1 and tco2 mutants was quantitatively measured as described in Materials and Methods. (C
and D) Northern blot analysis for monitoring expression levels of genes (FCY1 [cytosine deaminase, CNAG_00613.2], FCY2 [cytosine permease,
CNAG_01681.2], FCY4 [cytosine permeases, CNAG_04276.2], and FUR1 [uracil phosphoribosyltransferase, CNAG_02337.2]) involved in flucytosine uptake
and metabolism. Total RNA isolated from the WT strain and tco1, tco2, and hog1 mutants grown at 30°C for 90 min in YPD medium with or without 25
g/ml of flucytosine (5-FC) was used for Northern blot analysis by using the gene-specific probes listed in Table S2 in the supplemental material.
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FIG 2 Transcriptome analysis of flucytosine-responsive genes in C. neoformans. (A and B) Hierarchical clustering of the expression profiles of 177 flucytosine
stress-specific response genes in the WT strain and tco1, tco2, and hog1 mutants is illustrated (P  0.05,  2-fold). The change (fold) is illustrated by color (see the
bar scale). (A) All fold changes in each mutant with or without exposure to flucytosine were determined by normalizing (zero transformation) expression levels of each
gene to those in the WT strain without exposure to flucytosine (see Table S4 in the supplemental material). (B) All fold changes in response to flucytosine were determined
individually ineachmutantbynormalizing(zero transformation)expression levelsofeachgenewithexposure toflucytosine to thosewithoutexposure toflucytosine(seeTables
S5 and S6 in the supplemental material). (C) Venn diagram showing flucytosine-responsive genes in the WT strain and tco1, tco2, and hog1 mutants (see Table S7 in the
supplemental material). (D) Functional KOG (eukaryotic orthologous group) categories of genes differentially regulated by flucytosine treatment in the WT strain.
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show significant homology to any known proteins (see Table S5 in
the supplemental material). The remaining 59 genes had or-
thologs in S. cerevisiae or other fungi (Table 1; see Table S6 in the
supplemental material). Strikingly, however, none of the 59 genes
overlap with those of flucytosine-responsive genes in S. cerevisiae
(57). These data indicate that C. neoformans may employ a unique
set of genes to counteract flucytosine. Among flucytosine-
responsive genes with known or predicted functions, major
functional categories include signal transduction mechanisms
(17 genes), posttranslational modification and protein turnover
(16 genes), translation, ribosomal structure, and biogenesis (15
genes), and cell cycle control, cell division, and chromosome par-
titioning (8 genes) (Fig. 2D). These findings indicate that cellular
adaptation against flucytosine requires active modulation of var-
ious signaling and metabolic pathways, which may include the
Tco1/2-dependent two-component system. Flucytosine incorpo-
ration into DNA and RNA molecules may lead to production and
accumulation of truncated, nonfunctional, toxic proteins, which
explains why a number of genes that are involved in translation
and posttranslational modification or their quality control were
found to be regulated by flucytosine. Genes that are involved in
cell cycle control appear to be also required for cellular growth
control in the presence of a toxic nucleoside analogue. Notably, a
significant portion of the flucytosine-responsive genes in C. neo-
formans was found to be differentially regulated in the tco1,
tco2, or hog1 mutants compared to the WT strain (Fig. 2A to C;
see Table S7 in the supplemental material), indicating that the
two-component system and HOG pathways are major elements
for flucytosine resistance in C. neoformans.
Discovery of a flucytosine-responsive Mbp1/Swi4-like pro-
tein, Mbs1, in C. neoformans. Among the flucytosine-responsive
and two-component system-dependent genes, we focused on a
putative transcription factor which could potentially regulate ex-
pression of various flucytosine-defense genes in C. neoformans.
CNAG_07464.2 was predicted to encode a protein that is homol-
ogous to Mbp1 and Swi4 in S. cerevisiae. Hence, we named this
gene MBS1 (Mbp1- and Swi4-like protein 1). Mbp1 and Swi4
show limited but significant sequence homology to a family of
APSES transcription factors which are widely conserved in the
fungal kingdom but not in other eukaryotic kingdoms or pro-
karyotes (48). Protein domain analysis by the Pfam database (http:
//pfam.sanger.ac.uk/) revealed that Mbs1 contains a KilA-N
DNA-binding domain at the amino terminus which is found in
APSES proteins and Mbp1/Swi4-like proteins (see Fig. S2 in the
supplemental material). In addition, the ankyrin repeat domain,
which is known to mediate protein-protein interaction, is also
observed in CNAG_07464.2, similar to yeast Mbp1 (see Fig. S2 in
the supplemental material). Multiple-sequence alignment re-
vealed that the 97 amino acids of Mbs1 (Y to Y) showed limited
but significant homology to similar domains of other fungal
APSES proteins, whereas they are highly homologous to the DNA-
binding domains of Mbp1 and Swi4 (Fig. 3A).
We first confirmed whether MBS1 expression is controlled by
flucytosine via the two-component system. qRT-PCR clearly
showed that MBS1 is induced in response to flucytosine in the WT
and tco1 strains (Fig. 3B). In the tco2 mutant, however, basal
expression levels of MBS1 induction were slightly increased, but
the MBS1 expression was not further induced in response to flu-
cytosine (Fig. 3B). Interestingly, both basal and induced levels of
MBS1 were higher in the hog1 mutant than WT (Fig. 3B). North-
ern blot analysis confirmed these results (data not shown). These
data suggest that Tco2 and Hog1 play a role in controlling MBS1
expression.
To address whether Mbs1 is indeed required for flucytosine
resistance of C. neoformans, we generated two independent mbs1
mutants and confirmed that the two independent mbs1 mutants
are phenotypically identical (data not shown). The mbs1 mu-
tants and mbs1/MBS1 complemented strains grew as well as WT
in either solid or liquid YPD medium at 30°C and 37°C, which is a
host physiological temperature (see Fig. S4 in the supplemental
material). However, the mbs1 mutant exhibited a minor defect
in growth at a higher temperature (39°C) on solid YPD medium
(see Fig. S4A in the supplemental material), although this minor
growth defect at 39°C was not detectable in liquid YPD medium
(see Fig. S4B in the supplemental material), implying the potential
involvement of Mbs1 in thermotolerance. As expected from ex-
pression analysis of MBS1, the mbs1 mutants exhibited much
greater susceptibility to flucytosine than WT and its comple-
mented strain (Fig. 3C). Taken together, these results demonstrate
that Mbs1 is a flucytosine-responsive APSES-like protein that
controls the flucytosine resistance of C. neoformans.
Mbs1 affects ergosterol biosynthesis and thereby controls
polyene and azole drug susceptibility of C. neoformans. Because
MBS1 expression appeared to be regulated by Tco2 and Hog1, we
examined other Tco2- and Hog1-dependent phenotypes in C.
neoformans. Our prior study showed that the hog1, pbs2, ssk2,
and ssk1 mutants all showed increased susceptibility to ampho-
tericin B (AMB), whereas they were resistant to azole antifungal
drugs, such as fluconazole and ketoconazole (29). In contrast, the
tco2 mutant exhibited increased susceptibility to AMB but dis-
played WT levels of resistance to azole drugs (29). The mbs1
mutant exhibited greater susceptibility to AMB than WT, albeit to
a lesser extent than the hog1 mutant, but increased resistance to
ketoconazole and fluconazole compared to WT at levels almost
equivalent to those for the hog1 mutant (Fig. 4A).
The finding that the mbs1 mutant exhibited greater suscepti-
bility to AMB and resistance to azole drugs suggested that Mbs1
could be a transcription factor affecting ergosterol biosynthesis in
C. neoformans by controlling expression of ERG11, which encodes
lanosterol 14-demethylase, a target for the azole drugs. To ad-
dress this question, we monitored ERG11 expression in the mbs1
mutant compared to WT by qRT-PCR. Basal transcript levels of
ERG11 were much higher in the mbs1 mutant, albeit to a lesser
extent than the hog1 mutant, than in WT (Fig. 4B). Further-
more, actual cellular ergosterol contents measured in the mbs1
mutant were higher than those measured in WT but lower than
those measured in the hog1 mutant, which was in agreement
with ERG11 expression patterns (Fig. 4B and C). These results
suggested that differential susceptibility to polyene and azole
drugs in the mbs1 mutant is caused by altered amounts of ergos-
terol in the membrane (the polyene target) and Erg11 (the azole
target) produced by cells.
Mbs1 is involved in maintenance of membrane stability and
osmotic stress response. Changes in sterol content may affect
membrane structure without having a direct influence on the reg-
ulation of membrane-lipid metabolism (23, 41). Therefore, we
speculated that an increased ergosterol content may perturb nor-
mal cell membrane stability, as the hog1 mutant had increased
ergosterol content and was hypersusceptible to a membrane de-
tergent, such as SDS. Indeed, the mbs1 mutant exhibited hyper-
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Fold change in expression
Functional descriptionWTb tco1c tco2d hog1e
06980 STE11 1.593 1.528 0.262 1.592 Signal-transducing MEK kinase
01103 PRP11 3.242 0.635 1.181 2.135 Subunit of the SF3a splicing factor complex, required for spliceosome
assembly
04521 AIF1 1.676 0 0.309 0.54 Mitochondrial cell death effectors
01412 PAH1 1.211 0.104 0.243 0.202 Mg2-dependent phosphatidate (PA) phosphatase
04604 WRS1 1.331 0.288 0.589 0.184 Cytoplasmic tryptophanyl-tRNA synthetase, aminoacylates
tryptophanyl-tRNA
00689 ALG1 2.168 0.9 1.238 0.376 Mannosyltransferase
04451 POP1 1.506 0.603 1.109 0.04 Subunit of both RNase MRP, which cleaves pre-rRNA, and nuclear RNase P
07590 VMA5 1.694 0.184 1.077 0.162 Subunit C of the eight-subunit V1 peripheral membrane domain
04636 MCA1 1.742 0.151 1.471 0.47 Putative cysteine protease similar to mammalian caspases
07529 ILV1 1.411 0.997 0.413 1.133 Threonine deaminase, catalyzes the first step in isoleucine biosynthesis
03789 MRT4 1.784 0.377 1.805 0.895 Protein involved in mRNA turnover and ribosome assembly, localizes to the
nucleolus
02940 VNX1 3.929 0.667 2.344 2.183 Low-affinity vacuolar membrane-localized monovalent cation/H antiporter
02812 ARG3 1.17 0.054 0.859 0.695 Ornithine carbamoyltransferase (carbamoylphosphate:L-ornithine
carbamoyltransferase)
01626 ADA2 1.777 1.581 1.5 0.063 Transcription coactivator
04902 HRD3 1.329 1.148 0.775 0.183 Resident protein of the endoplasmic reticulum
05898 MET8 2.684 2.341 0.509 0.847 Bifunctional dehydrogenase and ferrochelatase
01885 PAP2 1.381 0.23 0.744 0.464 Catalytic subunit of TRAMP (Trf4/Pap2p-Mtr4p-Air1p/2p)
02233 MEC1 1.199 0.415 0.442 0.31 Genome integrity checkpoint protein
02020 SWC4 1.702 0.787 0.932 0.244 Component of the Swr1p complex
01175 GOT1 1.112 1.642 1.824 1.635 Present in early Golgi cisternae
07464 MBP1 1.805 0.428 0.466 0.502 Transcription factor involved in regulation of cell cycle progression from G1
to S phase
03127 RPS23B 1.368 0.551 0.999 0.614 Ribosomal protein 28 (rp28) of the small (40S) ribosomal subunit
02288 SFC1 2.147 0.963 0.451 0.952 Mitochondrial succinate-fumarate transporter
06223 SIZ1 2.274 0.911 0.309 0.848 SUMO/Smt3 ligase that promotes the attachment of sumo (Smt3p)
06828 AVT3 1.86 0.752 0.556 0.174 Vacuolar transporter
03565 PMA1 3.328 1.225 0.146 1.518 Plasma membrane H-ATPase, pumps protons out of the cell
03291 GRH1 2.6242 0.376 0.042 1.274 Acetylated, cis-Golgi apparatus-localized protein
01592 STE14 4.076 0.596 0.472 0.082 Farnesyl cysteine-carboxyl methyltransferase
00389 IBA57 1.368 0.653 0.296 0.268 Mitochondrial matrix protein
00640 RPS4A 2.057 0.723 0.232 0.198 Protein component of the small (40S) ribosomal subunit
01170 RPS17A 1.97 1.188 0.446 0.021 Ribosomal protein 51 (rp51) of the small (40S) ribosomal subunit
05671 OXR1 1.309 0.848 0.07 1.729 Required for normal levels of resistance to oxidative damage
02884 PSF2 1.461 0.084 0.473 0.968 Subunit of the GINS complex (Sld5p, Psf1p, Psf2p, Psf3p)
00703 RPL31A 2.008 0.14 0.765 1.303 Protein component of the large (60S) ribosomal subunit
05862 RAD10 2.384 0.349 0.978 1.827 Single-stranded DNA endonuclease (with Rad1p)
02294 ADE2 2.799 0.083 0.707 1.184 Phosphoribosylaminoimidazole carboxylase
02309 FPR2 1.305 0.122 0.649 1.124 Membrane-bound peptidyl-prolyl cis-trans isomerase (PPIase)
05248 APL2 1.745 0.01 0.082 1.353 Beta-adaptin, large subunit of the clathrin-associated protein (AP-1) complex
03078 NPP1 2.013 0.629 0.525 1.165 Nucleotide pyrophosphatase/phosphodiesterase family member
05134 CAR2 1.095 0.908 0.817 1.323 L-Ornithine transaminase (OTAse)
06447 RPL17A 1.624 1.206 0.536 0.284 Protein component of the large (60S) ribosomal subunit
03352 FRA2 2.823 3.459 1.273 0.939 Protein involved in negative regulation of transcription of iron regulon
06510 APC2 1.005 0.11 1.361 0.501 Subunit of the anaphase-promoting complex/cyclosome (APC/C)
07531 SNO1 1.321 0.109 1.14 0.245 Protein of unconfirmed function, involved in pyridoxine metabolism
01976 RPL23B 2.358 0.336 1.258 0.205 Protein component of the large (60S) ribosomal subunit
03150 FLX1 1.842 0.459 1.245 0.411 Protein required for transport of flavin adenine dinucleotide (FAD)
00672 RPS11A 2.736 0.921 2.743 1.379 Protein component of the small (40S) ribosomal subunit
02754 RPS12 1.704 0.302 2.128 1.423 Protein component of the small (40S) ribosomal subunit
a S. cerevisiae identifier, the name of the S. cerevisiae gene orthologous to the corresponding C. neoformans gene.
b Log2[(WT  5FC)/(WT  5FC)], where (WT  5FC) and (WT  5FC) indicate expression levels of each gene in the wild-type strain with or without flucytosine (5FC)
treatment, respectively.
c Log2[(tco1  5FC)/(tco1  5FC)], where (tco1  5FC) and (tco1  5FC) indicate expression levels of each gene in the tco1 mutant with or without flucytosine (5FC)
treatment, respectively.
d Log2[(tco2  5FC)/(tco2  5FC)], where (tco2  5FC) and (tco2  5FC) indicate expression levels of each gene in the tco2 mutant with or without flucytosine (5FC)
treatment, respectively.
e Log2[(hog1  5FC)/(hog1  5FC)], where (hog1  5FC) and (hog1  5FC) indicate expression levels of each gene in the hog1 mutant with or without flucytosine (5FC)
treatment, respectively.
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susceptibility to SDS, similar to the hog1 mutant (Fig. 5A). We
addressed whether defective membrane stability also affected re-
sistance to osmotic stress. Similar to the hog1 mutant, the mbs1
mutant was more susceptible to high concentrations of NaCl (data
not shown) and KCl than WT (Fig. 5B). In conclusion, Mbs1
modulates cell membrane stability and resistance to the osmotic
stress response.
Mbs1 is required for genotoxic and oxidative stress re-
sponses. In S. cerevisiae, Mbp1 and Swi4 play redundant roles in
cell cycle regulation (8, 25, 31). Furthermore, our prior study
demonstrated that Hog1 is also involved in defense against DNA-
damaging agents (29). Therefore, we addressed whether Mbs1
controls cellular responses against genotoxic stresses, which may
confer DNA damage and subsequent cell cycle arrest. We tested
cellular susceptibility to two DNA-damaging agents, hydroxyurea
(HU) and methyl methanesulfonate (MMS). HU is a ribonucle-
otide reductase inhibitor which blocks DNA synthesis and hinders
the deoxynucleoside triphosphate pool expansion during G1-to-
S-phase transition (30). MMS is a DNA-alkylating agent which
causes DNA fragmentation by inducing DNA double-strand
breaks (38). The mbs1 mutant exhibited hypersusceptibility to
HU, but not to MMS (data not shown), which was very similar to
results for the hog1 mutant (Fig. 6A). Interestingly, however, the
mbs1 mutant displayed extreme resistance to thiabendazole
(TBZ), a microtubule-destabilizing drug, whereas both the tco1
and tco2 mutants but not the hog1 mutant exhibited minor
TBZ resistance (Fig. 6A). Mutations perturbing centromere or
kinetochore function are often TBZ susceptible.
In oxidative stress response, the mbs1 mutant exhibited phe-
notypes similar to those of the hog1 and tco2 mutants. We
tested cellular susceptibility to hydrogen peroxide (H2O2) and di-
amide. H2O2 is one of the reactive oxygen species which can be
endogenously generated during oxygen-consuming metabolism
and induces protein thiol modification and radical formation. In
contrast, diamide is an exogenous oxidant which is more specific
toward thiol groups with glutathione but does not induce radical
formation. Cellular responses to diamide and H2O2 are known to
be different (see the review in reference 37). Similar to the hog1
and tco2 mutants, the mbs1 mutant displayed increased sus-
ceptibility and resistance to H2O2 and diamide, respectively (Fig.
FIG 3 Identification, expression analysis, and functional characterization of MBS1 in flucytosine susceptibility of C. neoformans. (A) Multiple-sequence
alignment of the APSES-like DNA-binding domain of Mbs1 with similar domains of other APSES and Mbp1/Swi4 proteins. Each abbreviation indicates the
following: AnStuA, Aspergillus nidulans StuA; NsAsm1, Neurospora crassa Asm1; ScPhd1 and ScSok2, Saccharomyces cerevisiae Phd1 and Sok2, respectively;
CaEfg1, Candida albicans Efg1; ScSwi4 and ScMbp1, S. cerevisiae Swi4 and Mbp1, respectively; CnMbs1, Cryptococcus neoformans Mbs1. Residues in dark shades
are identical, and homologous residues are included in light shades. Asterisks and closed circles indicate identical and similar residues, respectively, between
APSES and APSES-like proteins. Identical residues between ScMbp1/Swi4 and CnMbs1 are marked with a solid-line box. (B) qRT-PCR for monitoring MBS1
expression patterns in the WT strain (H99) and tco1, tco2, and hog1 mutants during flucytosine (5-FC) treatment. Total RNA isolated from each strain
grown at 30°C for the indicated incubation time (90 min) in YPD medium with or without 25 g/ml of flucytosine was used. Data were normalized by using ACT1
as a control, and relative gene expression indicates MBS1 expression of each strain compared to that of WT at zero time point. (C) Flucytosine susceptibility test.
Each C. neoformans strain (the WT [H99], hog1 [YSB64], tco1 [YSB278], tco2 [YSB281], mbs1 [YSB 488], and mbs1/MBS1 [YSB1195] strains) was grown
overnight at 30°C in liquid YPD medium, 10-fold serially diluted (1 to 104 dilutions), and spotted (3 l of dilution) on YPD agar containing the indicated
concentrations of flucytosine.
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6B). In contrast, the mbs1 mutant did not exhibit any increased
susceptibility or resistance to fludioxonil (an inducer of intracel-
lular glycerol accumulation), the heavy metal CdSO4, or tert-butyl
hydroperoxide, unlike the hog1 mutant (see Fig. S5 in the sup-
plemental material). Taken together, these results suggested that
Mbs1 is required for genotoxic stress response by potentially con-
trolling cell cycle regulation and oxidative stress response.
Mbs1 modulates pathogenicity and the host immune re-
sponse to infection. Next we measured the ability of the mbs1
mutant to produce virulence factors of C. neoformans because
these attributes are also controlled by the two-component system
and the HOG pathway. At physiological temperature (37°C), the
mbs1 mutant produced much lower levels of melanin than WT,
FIG 4 Role of Mbs1 in antifungal drug susceptibility and ergosterol biosynthesis. (A) Each C. neoformans strain described in Fig. 3B was grown overnight at 30°C
in liquid YPD medium, 10-fold serially diluted (1 to 104 dilutions), and spotted (3 l of dilution) on YPD agar containing the indicated concentrations of
amphotericin B, ketoconazole, and fluconazole. (B) Quantitative RT-PCR showing transcript levels of ERG11 in the WT strain and hog1 and mbs1 mutants.
For qRT-PCR, MBS1 expression data obtained from three independent biological replicates with three technical replicates were normalized by using ACT1 as a
control. Relative gene expression indicates ERG11 expression levels normalized to those of the WT strain. (C) Cellular ergosterol content was measured as
described in Materials and Methods. The graph demonstrates relative increase in ergosterol content compared to WT. Each bar demonstrates the average from
four independent experiments, and error bars indicate the standard deviation.
FIG 5 Role of Mbs1 in cell membrane integrity and osmotic stress response.
Each C. neoformans strain described in Fig. 3B was grown overnight at 30°C in
liquid YPD medium, 10-fold serially diluted, and spotted (3 l of dilution) on
YPD agar containing the indicated concentrations of SDS (A) or YP agar con-
taining the indicated concentration of KCl (B).
FIG 6 Role of Mbs1 in genotoxic and oxidative stress response. Each C. neo-
formans strain described in Fig. 3B was grown overnight at 30°C in liquid YPD
medium, 10-fold serially diluted (1 to 104 dilutions), and spotted (3 l of
dilution) on YPD agar containing the indicated concentrations of HU (70
mM) or TBZ (11 g/ml) for genotoxic stress susceptibility test (A) and H2O2
(2.5 mM) or diamide (3 mM) for oxidative stress susceptibility test (B).
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although the melanin synthesis defect of the mbs1 mutant was
not as pronounced as that of the cac1 mutant, which is defective
in cyclic AMP signaling (Fig. 7A). Similarly, the mbs1 mutant
also exhibited a minor defect in capsule production compared to
WT (Fig. 7B).
The role of Mbs1 in virulence factor production of C. neofor-
mans prompted us to investigate whether Mbs1 is required for the
pathogenicity of C. neoformans. The mbs1 mutant exhibited re-
duced virulence compared to WT in a murine survival model of
systemic cryptococcosis (Fig. 8A). While mice infected with the
WT strain became moribund 18 to 24 days postinfection, mice
infected with the mbs1 mutant did not show illness until 26 days
postinfection. In contrast to WT infections, animals infected with
the mbs1 mutant strain did not develop signs of neurological
involvement. On the basis of physical signs of weight loss coupled
with labored breathing, mice infected with the mbs1 mutant
strain appear to have succumbed to the pulmonary infection. In
contrast, the mbs1/MBS1 complemented strains exhibited WT
levels of virulence. When fungal burden was measured in mori-
bund animals, the lungs, spleen, and brain from mice infected
with the mbs1 mutant showed reduced fungal burden compared
to the WT and mbs1/MBS1 complemented strains (Fig. 8B and
data not shown).
During host infection, a subpopulation of C. neoformans un-
dergoes cell size enlargement (up to 100 m), which is particularly
stimulated by coinfection with opposite-mating-type cells. The
titan cells are uninucleate and polyploid and exhibit reduced
phagocytosis (45, 56). As seen previously, titan cells comprised
approximately 21% of the total cryptococcal cell population in the
lungs of mice infected with the H99 WT strain (Fig. 8C). Disrup-
tion of MBS1 led to a significant decrease (12%, P  0.0015) in
titan cell production in mice infected with the mbs1 mutant
strain. Restoring expression of MBS1 in the mbs1/MBS1 com-
plemented strain resulted in enhanced titan cell formation. These
data suggest that Mbs1 is involved in titan cell formation and may
affect interactions with the host by this mechanism.
A strong Th2 response to C. neoformans has been well charac-
terized in mice; the response is nonprotective and does not pro-
mote clearance of the organism (10, 15). Dissemination from the
lungs to the central nervous system (CNS) occurs readily during
infection with highly virulent strains such as H99, resulting in
cryptococcoma formation in the lungs and brains of infected an-
imals (13). As seen in Fig. 8A, animals infected with the mbs1
mutant succumbed to the infection, even with the defects in vir-
ulence factor and titan cell production exhibited by this strain.
Yet, animals infected with the mbs1 mutant never exhibited neu-
rological symptoms and appeared instead to succumb to the pul-
monary infection. One possible reason for this could be differ-
ences in the host immune response to the two organisms. To begin
characterizing whether the host response to the mbs1 mutant
strain contributed to pathogenicity, we examined lung and brain
tissue sections at 21 days postinfection from animals infected with
either the WT or mbs1 strain.
Extensive proliferation of C. neoformans was evident through-
out the lung tissue from mice infected with the WT strain (Fig. 9A
and C); only small areas at the periphery of the lung lobes re-
mained uninfected. Large areas of lung parenchyma exhibited al-
veoli distended with organisms of various sizes, myriads of very
small organisms, and various numbers of larger organisms (Fig.
9C). Scattered multifocal infiltrates of low numbers of polymor-
phonuclear leukocytes and/or foamy macrophages were found
near bronchioles and blood vessels. Low to moderate numbers of
lymphocytes were seen surrounding occasional blood vessels,
bronchi, and bronchioles. The bronchial epithelium appeared to
be undergoing mucinous metaplasia in severely affected areas
(data not shown). Similar infections and host responses were ob-
served with the mbs1/MBS1 complemented strain (data not
shown).
Conversely, in lungs infected with the mbs1 mutant, a larger
amount of the lung field was relatively intact, with only occasional
organisms identified within alveoli (Fig. 9B). Areas in which or-
ganisms were present had very dense pulmonary consolidation
with large numbers of foamy macrophages present, many of
which contained cryptococci (Fig. 9D). These areas also had thick-
ened alveolar septa with marked type 2 cell hyperplasia and mild
fibroplasia. Other foci of organisms within the pulmonary paren-
chyma appeared to be surrounded by dense infiltrates of polymor-
phonuclear leukocytes, often with associated necrosis. These re-
sults suggest that the host response in the lungs to the mbs1
mutant is distinctly different from the response to the highly vir-
ulent H99 strain.
FIG 7 Mbs1 is involved in production of melanin and capsule. (A) For mel-
anin assay, the WT (H99), cac1 (YSB42), mbs1 (YSB488), and mbs1/MBS1
(YSB1195) strains were spotted onto agar-based L-DOPA and Niger seed me-
dia containing the indicated concentration of glucose, grown at either 30°C or
37°C for 5 to 7 days, and photographed. (B) Capsule synthesis levels of C.
neoformans strains (WT [H99], cac1 [YSB42], mbs1 [YSB488], and mbs1/
MBS1 [YSB1195] strains) were quantitatively measured by using hematocrit,
as described in Materials and Methods. The relative capsule volume of the cells
was measured by calculating the ratio of the length of packed cell volume
phase/length of total volume phase. Two independent experiments with trip-
licates were performed. Statistical analysis was performed by using the Bonfer-
roni multiple-comparison test. NS, not significant; , P  0.001.
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Because the mbs1 mutant-infected animals did not exhibit
signs of neurological involvement, we analyzed brain sections to
look for differences in pathology within the CNS. Brain sections
from mice infected with the WT strain had multifocal aggrega-
tions of Cryptococcus within the parenchyma with no evidence of
inflammation (Fig. 9E). Organisms were also visualized multifo-
cally within the meninges and immediate submeningeal locations
(data not shown). In these areas, occasional polymorphonuclear
leukocytes, microglial cells, or lymphocytes were present, espe-
cially in perivascular locations. In contrast, brain sections from
mice infected with the mbs1 mutant contained fewer foci of or-
ganisms. The infected areas had fewer identifiable organisms, and
the foci were infiltrated by polymorphonuclear leukocytes, astro-
cytes, and glial cells (Fig. 9F). Marked pyogranulomatous to
purely granulomatous inflammation was associated with crypto-
cocci within the meninges and penetrated into the superficial ce-
rebral cortex (data not shown). Small foci of necrosis were present
within the parenchyma with what appeared to be degenerate neu-
trophilic debris and cryptococci within the necrotic center (Fig.
9F). To our knowledge, these types of cells have not been previ-
ously reported surrounding cryptococcomas within the brains of
infected animals.
DISCUSSION
The present study investigates the genome-wide flucytosine-
response regulatory mechanism in C. neoformans with connection
FIG 8 Mbs1 is required for virulence of C. neoformans. (A) Groups of A/J mice were infected with 5  104 cells of MAT WT (H99), mbs1 (YSB488), and
mbs1/MBS1 complemented (YSB1195) strains by intranasal inhalation. Survival was monitored for 33 days postinfection. (B) A/J mice were infected as
indicated for panel A. Fungal burden (CFU/g tissue) was determined by plating homogenates of lung or brain tissue onto YPD at 21 days postinfection. P values
for lungs: 0.05 (WT versus mbs1), 0.949 (mbs1/MBS1 versus WT), and 0.096 (mbs1 versus mbs1/MBS1). P values for brains: 0.0747 (WT versus mbs1),
0.5359 (WT versus mbs1/MBS1), and 0.0302 (mbs1/MBS1 versus mbs1). (C) Mice were infected with 5  106 cells of MAT WT (H99), mbs1 (YSB488),
and mbs1/MBS1 complemented (YSB1195) strains by intranasal inhalation. Cells were obtained by bronchial alveolar lavage at 3 days postinfection, fixed in
formaldehyde, and analyzed by microscopy for size and morphology. More than 300 cells per animal were examined. Representative images are shown. Numbers
indicate the percent titan cell formation  SD. P values in pairwise comparisons: 0.0112 (WT versus mbs1), 0.0294 (WT versus mbs1/MBS1), and 0.0015
(mbs1 versus mbs1/MBS1). Black arrows, titan cells. Bars  10 m.
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to the two-component system and HOG signaling pathway, which
is a first in the human meningitis-causing fungal pathogen. As a
key discovery of this transcriptome analysis, we identified the
MBS1 gene, encoding an APSES-like transcription factor, whose
expression is modulated upon flucytosine treatment. Both Tco2
and Hog1 repress basal expression levels of MBS1, whereas only
Tco2 appeared to be involved in flucytosine-responsive induction
of MBS1. APSES-like proteins have never been studied before in
C. neoformans. Phenotypic analyses of mbs1 deletion mutants re-
vealed that Mbs1 plays pleiotropic functions in C. neoformans,
including regulation of susceptibility to diverse antifungal drugs
such as flucytosine, azole, and polyene drugs; ergosterol biosyn-
thesis; cell membrane stability; genotoxic, oxidative, and salt stress
responses; in vitro and in vivo morphological differentiation; vir-
ulence factor production; and virulence of the pathogen.
Flucytosine is one of the most widely used antifungal drugs for
treatment of deadly cryptococcosis, although it is generally used in
combination with AMB due to the tendency to develop drug re-
sistance. Despite its importance, regulatory and resistance mech-
anisms for flucytosine are poorly understood in C. neoformans and
have generally been assumed to be similar to those in S. cerevisiae
and C. albicans. Several lines of evidence provided in this study
indicate that C. neoformans has developed distinct defense mech-
anisms against flucytosine. First, the role of sensor histidine ki-
FIG 9 Mbs1 infection leads to an altered host immune response. Mice were infected with 5  104 cells of MAT WT (H99) and mbs1 (YSB488) strains by
intranasal inhalation. Lungs sections were stained with H&E at 21 days postinfection. (A and C) WT-infected lungs. Arrowheads, foamy macrophages and/or
polymorphonuclear cells; arrows, area of lymphocyte infiltration. (B and D) mbs1 mutant-infected lungs. Arrowheads, dense infiltrates of polymorphonuclear
cells with and without necrosis; arrows, type 2 cell hyperplasia and mild fibroplasia. (E) WT-infected brain cryptococcoma. (F) mbs1 mutant-infected brain
cryptococcoma. Arrowheads, neutrophilic debris and necrosis. Bars  4 mm (A and B), 200 m (C and D), and 100 m (E and F).
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nases in flucytosine resistance has not been reported in any other
organisms. In particular, Tco2 is a unique sensor histidine kinase
observed only in C. neoformans which carries two response regu-
lator and histidine kinase domains in a single polypeptide. Dele-
tion of TCO2 confers strong resistance to flucytosine in C. neofor-
mans, whereas mutation of TCO1 increases susceptibility to
flucytosine, indicating that the pathogen employs the two-
component system for modulating the flucytosine-response path-
way. Second, flucytosine-responsive transcriptome patterns in C.
neoformans were significantly different from those in S. cerevisiae
(57). Among the 177 flucytosine-regulated genes in C. neofor-
mans, none of them overlapped with those in S. cerevisiae, which
strongly suggests that C. neoformans employs a distinct set of genes
to respond to flucytosine. To further support this, a majority of
the flucytosine-regulated genes in C. neoformans (118 out of 177,
67%) appeared to have no known functions in other fungi. Taken
together, C. neoformans utilizes a unique defensive mechanism
against flucytosine treatment.
Among the 59 evolutionarily conserved flucytosine-responsive
genes, STE14 (CNAG_01592.2), encoding the isoprenylcysteine
carboxyl methyltransferase (ICMT), was the most highly upregu-
lated (	16-fold) in the WT strain but not in the tco1, tco2, and
hog1 mutants (Table 1). These data could be related to our pre-
vious finding showing that Ras1 promotes flucytosine resistance
in C. neoformans (28). Ras1 undergoes two essential posttransla-
tional modifications, palmitoylation and prenylation, which are
required for proper cellular localization and function of the small
GTPase protein (44). Nichols et al. (44) demonstrated that point
mutation of a cysteine residue (C207A) in the CAAX motif causes
abnormal cellular localization of Ras1, which subsequently abol-
ishes its normal function, such as promoting growth at host phys-
iological temperature, indicating that prenylation of the CAAX
motif is essential for Ras1 in C. neoformans. Ste14 is required for
prenylation of CAAX proteins by transferring a methyl group to
the C-terminal prenylcysteine. The increased expression of the
STE14 ortholog may enhance or facilitate prenylation and mem-
brane localization of Ras1 to the plasma membrane, affecting its
resistance to flucytosine. This possibility is under investigation.
Among the flucytosine-regulated C. neoformans genes, the
APSES-like Mbs1 transcription factor, homologous to the yeast
Mbp1 and Swi4, which play redundant roles during the G1/S tran-
sition in cell cycle progression (31), is most notable because no
other APSES or APSES-like proteins have hitherto been charac-
terized in the pathogen and their involvement in flucytosine resis-
tance has not been reported in any other fungal species. On the
basis of analysis of the Cryptococcus genome database, Cryptococ-
cus does not appear to contain APSES proteins that are directly
orthologous to other fungal APSES proteins. In addition to the
Mbp1/Swi4 ortholog (CNAG_07464.2), C. neoformans possesses
another APSES-like ortholog (CNAG_01438.2) which is also ho-
mologous to Mbp1 and Swi4. However, the yeast Swi6 shares
higher sequence identity to CNAG_01438.2 than Mbp1 and Swi4.
Unlike S. cerevisiae and C. albicans, it appears that C. neoformans
contains a single nonessential Mbp1/Swi4-like protein (Mbs1).
Our array results show that SWI6 was not regulated in response to
flucytosine (see Tables S4 and S5 in the supplemental material),
indicating that Mbs1 may be involved in flucytosine response in-
dependently of cell cycle progression. Recently, Walsh et al. re-
ported that expression of RNR2, which encodes ribonucleotide
reductase, is induced by DNA-damaging agents, such as MMS,
and is regulated by Mbp1 in S. cerevisiae (53). Therefore, it is
possible that flucytosine treatment hampers DNA synthesis,
which subsequently activates RNR2 through the Mbs1 transcrip-
tion factor.
Both the two-component system and the HOG pathway are
likely to be the upstream signaling pathways for Mbs1, based on
several observations made by this study. First, flucytosine-
mediated induction of MBS1 was not observed in the tco2 mu-
tants in both DNA microarray and Northern blot/qRT-PCR anal-
yses. In contrast, both basal and induced levels of MBS1 were
higher in the hog1 mutant than WT. Second, a number of phe-
notypes of the mbs1 mutant are closely related to those of the
tco2 or hog1 mutants. For example, the phenotypes of the
mbs1 mutant, including enhanced ergosterol production and
increased sensitivity to a DNA-damaging agent (HU), membrane
destabilizer (SDS), and high salt conditions, were very similar to
those of the hog1 mutant. At this point, the exact Mbs1 regula-
tory mechanism in the two-component system and HOG path-
ways remains unknown. Whether Mbs1 is directly activated by
Hog1 needs to be addressed in future studies. However, other
HOG-independent signaling pathways are also likely to regulate
Mbs1 because several phenotypes of the mbs1 mutant, such as
extreme TBZ resistance and production of capsule and melanin,
could not be explained only by signaling through the HOG
pathway.
The role of APSES proteins in ergosterol biosynthesis has been
reported in C. albicans, although its regulatory mechanism ap-
pears to be different from that of Mbs1 in C. neoformans. Deletion
of EFG1 diminishes cellular ergosterol content by decreasing ex-
pression levels of ERG11 and enhances membrane fluidity and
passive diffusion of drugs (47). Hence, the homozygous efg1/
efg1 mutant is more susceptible to both polyene and azole drugs
than wild type (47). In contrast, our study revealed that the mbs1
mutant exhibited increased expression of ERG11 and actual cellu-
lar ergosterol contents in C. neoformans. This phenotype of the
mbs1 mutant is similar to that of the hog1 mutant. In S. cerevi-
siae, ERG11 has been discovered to be SBF targets through chro-
matin immunoprecipitation-on-chip (ChIP-chip) analysis (25).
Although the role of Swi4 in controlling ergosterol biosynthesis
was not directly proven in S. cerevisiae, this finding and our data
suggest that the Mbp1/Swi4 ortholog could be generally involved
in ergosterol biosynthesis.
Supporting the role of Mbs1 in ergosterol biosynthesis, dele-
tion of MBS1 increased AMB susceptibility and azole drug resis-
tance. Taken together with our previous data (29), it is highly
likely that diverse signaling components of the two-component
system and HOG pathway could be excellent antifungal targets for
treatment of cryptococcosis, particularly when combined with
other known antifungal agents. First, the potential inhibitors of
Tco2, Ssk1, Ssk2, Pbs2, and Hog1 could have synergistic anticryp-
tococcal effects with AMB. Among them, Tco2 and Ssk1 are in-
volved in the two-component phosphorelay system, making them
attractive targets for development of novel antifungal agents be-
cause the corresponding signaling components do not exist in
humans. Second, the potential inhibitors of Tco1, Mbs1, and Ras1
could have synergistic anticryptococcal effects with flucytosine.
Development of Mbs1-specific inhibitors could be particularly
useful because they will show synergistic antifungal activity with
AMB and flucytosine, the combination of which is currently most
widely used for the initial therapeutic approach for treatment of
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cryptococcosis. Furthermore, monotreatment with Mbs1-specific
inhibitors could be also clinically useful since it was shown that
Mbs1 inhibition alone debilitates virulence of C. neoformans
(Fig. 8).
At this point, it is not clear how the production of two major
virulence factors, capsule and melanin, and in vivo virulence of C.
neoformans are controlled by Mbs1. The reduced virulence ob-
served in the mbs1 mutant appears to be caused by multiple
factors. Besides decreased production of capsule and melanin, in-
ability to confer an appropriate cellular response against diverse
environmental stresses and weak cell membrane stability with in-
creased cellular ergosterol content could also contribute to re-
duced virulence of the mbs1 mutant. Furthermore, debilitated
titan cell formation may render the mbs1 mutant more suscep-
tible to phagocytosis, which could facilitate its clearance by the
host immunological system. On the basis of our histopathology
results, as well as the differences in morbidity and mortality ob-
served in infected animals, it is clear that the host immune re-
sponse to the mbs1 mutant is altered relative to a highly virulent
strain such as H99. The pathology observed in the lungs of mbs1
mutant-infected mice appears to be similar to that reported pre-
viously in interleukin-4 (IL-4)/IL-13/ mice infected with strain
H99 (58), suggesting that infection with the mbs1 mutant strain
may alter the host immune response to pulmonary infection. This
altered immune response could explain the presence of numerous
host immune cells within the brains of mice infected with the
mbs1 mutant, specifically as it pertains to the presence of inflam-
matory cells not typically found in the brains of animals infected
by C. neoformans.
In future studies, several aspects of the regulatory mechanism
of Mbs1 need to be further addressed. First, in addition to Tco2
and Hog1, a full array of upstream signaling components modu-
lating expression or activity of Mbs1 needs to be elucidated. Sec-
ond, based on the pleiotropic roles of Mbs1, how the Mbs1-
dependent signaling pathway is functionally and structurally
connected to other signaling pathways in C. neoformans also needs
to be clarified. It is possible that the Skn7 response regulator might
be involved in functions of Mbs1 in regulation of some virulence
factors, such as melanin and oxidative stress response. In S. cerevi-
siae, Skn7 physically interacts with Mbp1, but not with Swi4 or
Swi6, via its coiled-coil domain and receiver domain and is di-
rectly associated with the G1 transcriptional machinery (12). In C.
neoformans, Skn7 controls melanin biosynthesis and Na salt and
oxidative stress adaptation (7). Therefore, functions of Mbs1 in
melanin and oxidative stress response could be related to those of
Skn7 in the pathogen. Potential molecular and genetic relation-
ships between Mbs1 and Skn7 in C. neoformans need further in-
vestigation.
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